GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinus Pharmaceuticals Inc (NAS:MRNS) » Definitions » Change In Other Working Capital

MRNS (Marinus Pharmaceuticals) Change In Other Working Capital : $2.12 Mil (TTM As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Marinus Pharmaceuticals Change In Other Working Capital?

Marinus Pharmaceuticals's Change In Other Working Capital for the quarter that ended in Sep. 2024 was $0.54 Mil. It means Marinus Pharmaceuticals's Other Working Capital increased by $0.54 Mil from Jun. 2024 to Sep. 2024 .

Marinus Pharmaceuticals's Change In Other Working Capital for the fiscal year that ended in Dec. 2023 was $2.61 Mil. It means Marinus Pharmaceuticals's Other Working Capital increased by $2.61 Mil from Dec. 2022 to Dec. 2023 .

Marinus Pharmaceuticals Change In Other Working Capital Historical Data

The historical data trend for Marinus Pharmaceuticals's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marinus Pharmaceuticals Change In Other Working Capital Chart

Marinus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Other Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 22.16 -4.27 2.61

Marinus Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.53 0.52 0.52 0.54

Marinus Pharmaceuticals Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marinus Pharmaceuticals Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Marinus Pharmaceuticals's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Marinus Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinus Pharmaceuticals Inc (NAS:MRNS) » Definitions » Change In Other Working Capital
Comparable Companies
CDMO RNA GHRS IMNM CGEM BMEA RAPT GNLX ORTX OCS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
MRNS:Mexico 0JYL:UK 61Y:Germany
Address
100 Matsonford Road, Suite 500, 5 Radnor Corporate Center, Radnor, PA, USA, 19087
Website
https://www.marinuspharma.com
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
Executives
Christina Shafer officer: Chief Commercial Officer 5 RADNOR CORPORATE CENTER, SUITE 500, 100 MATSONFORD ROAD, RADNOR PA 19087
Scott Braunstein director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Steven Pfanstiel officer: CFO 5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087
Joseph Hulihan officer: Chief Medical Officer 5 RADNOR CORP CENTER SUITE 500, 100 MATSONFORD RD, RADNOR PA 19087
Martha E Manning officer: VP, Gen. Counsel & Corp. Sec. 700 PENNSYLVANIA DR, EXTON PA 19341
Sarah B. Noonberg director 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Marvin Johnson director C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, STE. 110, CHESTERBROOK PA 19087
Elan Ezickson director AVEO PHARMACEUTICALS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Charles Austin director 5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Christine Berni Silverstein director C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Santiago Arroyo director C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Sara Nochur director 295 WOODCLIFF RD, NEWTON MA 02461
Nicole Vitullo director, 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Edward F Smith officer: Chief Financial Officer C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104